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Abstract
INTRODUCTION: Many genes are differentially expressed between androgen-dependent and androgen-independent
prostate cancer (CaP). Differential expression analysis and subtractive hybridization previously identified nine
genes expressed in intact mice bearing CWR22 tumors and castrated mice bearing recurrent CWR22 tumors
but not in regressed tumors. The objectives of this study were to develop an immunostaining method to dual-label
foci of proliferating tumor cells [the origin of castration-recurrent CaP (CR-CaP)], to determine which of the nine
candidate proteins were differentially expressed in proliferating versus nonproliferating cells at the onset of growth
after castration, and to test preclinical findings using clinical specimens of androgen-stimulated benign prostate
(AS-BP) and CaP (AS-CaP) and CR-CaP. METHODS: Paraffin-embedded, bromodeoxyuridine–injected CWR22 tu-
mors were hydrated, antigen-retrieved using high heat and high pressure, labeled for each of the nine antigens of
interest, visualized using peroxidase, and counterstained with hematoxylin. Mean optical density was calculated
for proliferating and nonproliferating areas using automated (nuclear staining) or manual (cytoplasmic staining)
image analysis. Prostate tissue microarray sections were immunostained and visually scored. RESULTS: Immuno-
histochemistry revealed higher nuclear expression of thioredoxin reductase 1 (TrxR1) in proliferating cells than
nonproliferating cells (P< .005). There were no statistical differences between cell types in the expression of other
proteins. TrxR1 expression was higher (P < .01) in CR-CaP compared with AS-BP or AS-CaP. CONCLUSIONS: In-
creased TrxR1 expression in CR-CaP was consistent with increased TrxR1 and BrdU expression at the onset of
growth in the CWR22 model. Thioredoxin reductase 1 should be targeted in an attempt to delay or prevent CaP re-
currence after castration.
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Introduction
Prostate cancer (CaP) remains the most common malignancy and
second leading cause of cancer deaths among males in the United
States [1]. Prostate cancer is androgen-dependent, and its growth is
mediated by an androgen receptor (AR)–regulated gene network.
Androgen deprivation therapy causes reduced AR expression [2],
apoptosis, decreased cell volume [3], and decline of serum prostate-
specific antigen (PSA). However, CaP eventually develops the ca-
pacity for recurrent growth in the absence of testicular androgens.
Many research investigators are comparing androgen-dependent and
castration-recurrent CaP (CR-CaP) in clinical specimens or androgen-
sensitive and androgen-independent CaP cell lines using molecular
approaches. These experiments may identify many genes whose ex-
pression is altered, only a few of which are critical for the development
of castration-recurrent growth.
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CWR22 is an androgen-dependent human CaP xenograft propa-
gated subcutaneously in nude mice. CWR22 resembles most human
CaP; CWR22 secretes PSA, undergoes tumor regression after andro-
gen deprivation therapy, and recurs as a palpable, growing, and ulti-
mately lethal tumor after several months without testicular androgens
[4–7]. In an earlier study [8], differential expression analysis was used
to identify gene transcripts that were down-regulated after castration
but up-regulated in castration-recurrent CWR22 despite the contin-
ued absence of testicular androgens. Androgen-regulated transcripts
included human kallikrein 2 (hk2), Nkx 3.1, α-tubulin, α-enolase,
and insulin-like growth factor binding protein 5 (IGFBP-5). Kim
et al. [9] used MIB-1 detection of Ki-67 and automated image anal-
ysis in paraffin sections of CWR22 tumors to determine the onset of
cellular proliferation after castration. The onset of cellular prolifera-
tion on day 90 coincided with an increase in serum PSA. An increase
in cellular proliferation was first observed on day 64 after castration.
The appearance of proliferating tumors that expressed PSA indicated
that these foci might be the precursors of CR-CaP tumors. In a sub-
sequent study [10], subtractive hybridization identified four gene
transcripts expressed in intact mice bearing CWR22 tumors and cas-
trated mice bearing recurrent tumors but not in regressed tumors.
Northern analysis confirmed temporal association with tumor
growth for these candidates: three were proliferation-associated and
not androgen-related [tomoregulin, translation elongation factor 1α
(EF-1α), Mxi-1] and one was proliferation-associated and androgen-
regulated [thioredoxin reductase 1 (TrxR1)].
Computer-assisted quantitative image analysis and immunochem-
istry have enabled in situ protein localization and protein quanti-
fication in formalin-fixed, paraffin-embedded tissue. Video image
analysis has been used to quantitate AR expression more precisely
than visual scoring [11,12]. Mean optical density (MOD) measure-
ments made using automated image analysis successfully quantified
the dependence of AR protein levels on serum androgen levels in the
CWR22 model [9]. Immunohistochemistry can colocalize proteins
of interest and cellular proliferation markers within the same cell.
The objective of this study was to develop an immunostaining
protocol to sequentially dual-label (peroxidase and fluorescence)
CWR22 tumors without diminishing the previously labeled protein
and to use computer-assisted image analysis to determine which of
the nine candidate proteins was differentially expressed in prolif-
erating versus nonproliferating cells 64 days after castration. The pro-
tein of interest would then be examined for overexpression in both
androgen-stimulated CaP (obtained from radical prostectomy speci-
mens) and CR-CaP (obtained from transurethral resection specimens
from men with urinary retention due to CaP recurrence during an-
drogen deprivation therapy).
Materials and Methods
CWR22 Tumors
CWR22 tumors 64 days after castration demonstrated larger foci
of proliferation than reported previously [9]. To study the earliest
onset of cellular proliferation after castration CWR22 tumors were
studied 50 days after castration.
Twenty nude mice were subcutaneously implanted with CWR22
cell suspensions containing 1 million cells bilaterally as described
[5,10,13]. Mice bearing castration-recurrent CWR22 tumors were in-
jected with 2.0 mg of bromodeoxyuridine (BrdU) per animal (Roche,
Palo Alto, CA) for 4 hours and killed by cervical dislocation. Tumors
were resected and immediately formalin-fixed and paraffin-embedded.
The Institutional Animal Care and Use Committee of the University
of North Carolina at Chapel Hill approved all procedures used.
Immunohistochemistry
Formalin-fixed, paraffin-embedded CWR22 tumors were cut into
6-μm histologic sections. The sections were deparaffinized, rehy-
drated through an alcohol gradient, and antigen-retrieved using
Citra buffer (Biocare, Walnut Creek, CA) for 3 minutes at 120°C
[14]. Cooled sections were incubated with a serum block, blocked
for endogenous peroxidase using 3% H2O2 for 5 minutes at 37°C,
and blocked with avidin biotin for 15 minutes at 37°C (Vector,
Burlingame, CA). Sections were incubated with either mouse mono-
clonal anti-hk2 (Mayo Clinic, Rochester, MN), goat polyclonal
anti–Nkx 3.1 (Santa Cruz Biotechnology, Santa Cruz, CA), goat poly-
clonal anti–IGFBP-5 (Santa Cruz Biotechnology), rat monoclonal
anti–α-tubulin (Abcam, Cambridge, UK), rabbit monoclonal anti–
non-neuronal enolase (NNE; Accurate Chemical, Westbury, NY),
rabbit polyclonal anti-TrxR1 (Upstate, Charlottesville, VA), mouse
monoclonal antitomoregulin (Sakamoto Laboratory, Japan), mouse
monoclonal anti–EF-1α (Upstate), or mouse monoclonal anti–Mxi-1
(BD Pharmigen, San Jose, CA) at 1:200 for 1 hour at 37°C. Sections
were incubated with the appropriate biotinylated secondary IgG
(Vector) 1:200 for 15 minutes at 37°C and ABC amplification (Vector)
1:200 for 15 minutes at 37°C. Specific signal was visualized using
diaminobenzidine (Vector) 1:200 for 5 minutes at 37°C. Sections
were counterstained with hematoxylin. Single-labeled sections were
antigen-retrieved a second time using high-pH Tris buffer (Biocare)
for 3 minutes at 120°C to expose DNA-incorporated BrdU [15].
Cooled slides were labeled with sheep polyclonal anti-BrdU (Abcam)
at 1:200 for 1 hour at 37°, followed by rhodamine-conjugated F(ab′)2
fragment (Jackson ImmunoResearch, West Grove, PA) at 1:200 for
15 minutes at 37°C. A fluorescent nuclear dye (4′,6-diamidino-2-
phenylindole) was used for proteins expressed in the cytoplasm.
Tissue Microarray
A high-density tissue microarray (TMA) was constructed using
formalin-fixed, paraffin-embedded human prostate specimens. The
tissue microarray was constructed from matched pairs of androgen-
stimulated benign prostate (AS-BP) and CaP (AS-CaP) from rad-
ical prostatectomy specimens from 23 men and CR-CaP from
transurethral resection specimens from 22 men using the Beecher
Instruments (Silver Spring, MD) manual tissue arrayer. Androgen-
stimulated benign prostate obtained by transurethral resection, colon
cancer, and mouse liver cores were included as internal controls for
standardization. Six-micrometer sections were cut from donor paraf-
fin blocks and stained with hematoxylin and eosin. A urologic pa-
thologist evaluated the tissue sections and identified BP and CaP.
The regions of interest were sampled by removing a 1.5-mm tissue
core. These cores were implanted into a recipient paraffin block to
create a TMA containing a total of 84 tissue cores.
Immunohistochemistry
A 6-μm histologic section was cut from the TMA and was de-
paraffinized, rehydrated through an alcohol gradient, and antigen-
retrieved using a Citra buffer (Biocare) for 3 minutes at 120°C.
The cooled section was incubated with a serum block, blocked for
endogenous peroxidase using 0.03% H2O2 for 5 minutes at 37°C
followed by a block of avidin biotin for 15 minutes at 37°C (Vector).
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The section was incubated with anti-TrxR1 1:200 for 1 hour at 37°C
[10]. The section was incubated with biotinylated antimouse IgG
(Vector) 1:200 for 15minutes at 37°C and ABC amplification (Vector)
1:200 for 15 minutes at 37°C. Specific signal was visualized using
diaminobenzidine (Vector) 1:200 for 5 minutes at 37°C. The section
was counterstained with hematoxylin.
Image Acquisition and Analysis
The image acquisition system consisted of a Leica DMRA2 micro-
scope (Leica Microsystems Inc, Bannockburn, IL) with a motorized
stage controller (Ludl Electronic Products Ltd, Hawthorne, NY), a
three-chip CCD camera with controller (Hamamatsu, Bridgewater,
NJ), and a FlashPoint 3D image grabber card (Integral Technologies,
Indianapolis, IN) in a Pentium 4–based personal computer. Image Pro
Plus 4.5 (MediaCybernetics, Carlsbad, CA) software was used to cap-
ture and store the images. Images with 24-bit color depth and spatial
resolution of 640 × 480 pixels were stored as uncompressed TIFF files.
Nuclear immunostaining. A flowchart illustrated the image anal-
ysis steps involved when the protein of interest was expressed in nu-
clei (TrxR1, Nkx 3.1, IGFBP-5, and tomoregulin; Figure 1). The
BrdU-immunostained fluorescent image and the peroxidase image
(immunostained with protein of interest) were captured from the
same location in the specimen. Stromal areas and regions of artifact
were removed from the peroxidase image. The fluorescent image was
used to create nuclear masks of proliferating nuclear areas and all nu-
clear areas. Histogram-based segmentation (Image Pro Plus 4.5) was
used to create a binary mask. The threshold was selected to make
nuclear boundaries visible. The mask was added to the peroxidase
image to create a proliferation image. The mask from proliferating
regions was inverted and added to the mask from all nuclear areas
before addition to peroxidase image to create a nonproliferation im-
age. Mean optical density was calculated for proliferating and non-
proliferating images using automated nuclear image analysis [12].
The parameters for image analysis were determined using a macro
in Image Pro Plus 4.5. The image background was set at white
(grayscale level = 255) for MOD calculations.
Cytoplasmic immunostaining. Automated nuclear analysis soft-
ware could not be used when the protein of interest was expressed
in the cytoplasm (hk2, α-tubulin, NNE, EF-1α, Mxi-1). The anal-
ysis was performed manually by visually selecting cytoplasmic areas
adjacent to the identified nuclear regions in proliferating and non-
proliferating images. Mean optical density was calculated from those
regions using Image Pro Plus 4.5.
Visual scoring. Epithelial and stromal regions from AS-BP, AS-
CaP, and CR-CaP cores on prostate TMA sections were visually
scored from 0 (staining same as background) to 4 (intense staining).
Statistical Analysis
Student’s paired t tests were performed on the MOD data sets
from proliferating versus nonproliferating nuclei or cytoplasm to de-
termine whether the differences between image pairs was statistically
Figure 1. Flowchart illustrating computer-assisted image analysis for images where protein of interest is expressed in nuclei. NP indi-
cates nonproliferating; P, proliferating.
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significant. A comparison of means (Student’s t test) was performed
to determine whether the difference in visual scores from epithelia or
stroma among different tissue types was statistically significant.
Results
Bromodeoxyuridine labeling required DNA denaturing with high-
pH buffer that did not degrade the peroxidase label, but BrdU label-
ing interfered with peroxidase immunostaining when performed first.
Super heating, high-pressure antigen retrieval was used twice on the
same slide at different pH. Antiproteins were optimized using high-
heat, high-pressure antigen retrieval and neutral pH Citra buffer.
The expression of four nuclear and five cytoplasmic proteins were
quantified in castration-recurrent CWR22 tumors 50 days after cas-
tration (Table 1). Thioredoxin reductase 1 was expressed at higher
levels in proliferating cells than in nonproliferating cells (P < .005).
The expression of hk2, Nkx 3.1, IGFBP-5, α-tubulin, NNE, tomor-
egulin, EF-1α, and Mxi-1 was similar between proliferating and non-
proliferating cells.
A total of 25 cores (9 benign prostatic hyperplasia, 8 AS-CaP, and
eight recurrent CaP) were found unsuitable for analysis on the pros-
tate TMA. Qualitative visual assessment demonstrated that TrxR1
was expressed at higher levels in CR-CaP than in AS-BP and AS-CaP
(Figure 2). Visual scoring revealed similar levels of immunostain-
ing in epithelia and stroma of AS-BP and AS-CaP tissue specimens
(Table 2). Castration-recurrent CaP exhibited higher levels of immu-
nostaining in both epithelia and stroma.
Discussion
To make direct comparison of protein expression in proliferating
versus nonproliferating cells, a total of 7 years were invested to eval-
uate different approaches. The goal was an immunostaining protocol
that allowed dual labeling of either Ki-67 or BrdU (primary label)
and other proteins of interest (second label). Recent publications
described the unique ability of high-heat, high-pressure antigen re-
trieval methods to yield good immunostaining results [14,16]. The
effect of repeated high-pressure antigen retrieval using differing pH
buffers on immunostaining quality was concerning, but the second
high-pH retrieval produced no noticeable loss of intensity of peroxi-
dase immunostaining. High-pressure antigen retrieval was reported to
increase endogenous peroxidase activity and nonspecific staining [17]
and nonspecific background increased slightly after two sequences
of high-pressure retrieval. Therefore, peroxidase was labeled before
the second antigen retrieval, which made the hydrogen peroxide
blocking step sufficient to quench this activity. A hybrid peroxidase/
fluorescent dual-labeling protocol was developed to derive robust
images for image analysis. Cell proliferation was determined using
fluorescent-labeled BrdU. The proliferating cells were identified
using fluorescence that did not interfere with image analysis for the
peroxidase-labeled primary. The method was demonstrated for simul-
taneous assessment of proliferation and protein expression.
Thioredoxin (Trx), and thioredoxin reductase (TrxR) comprise the
thioredoxin system, which exists in nearly all living cells. The system
is crucial for the maintenance of reduced intracellular redox environ-
ment, cellular growth, defense against oxidative stress, and control of
apoptosis [18]. The function of Trx as a disulfide reductase in mam-
malian cells depends on the activity of the selenoenzyme, TrxR [19],
Table 1. Expression of Nine Proteins in Castration Recurrent CWR22 Tumors.
Proteins Subcellular Localization Dual Method Using Quantitative
Image Analysis
MOD of High/Low Proliferation P*
hk2 C 0.212/0.213 .473
Nkx 3.1 N 0.891/0.913 .149
IGFBP-5 N 0.937/0.938 .821
α-tubulin C 0.410/0.425 .094
NNE C 0.366/0.356 .065
TrxR1 N 1.034/0.963 .003
Tomoregulin N 1.226/1.235 .685
EF-1α C 0.208/0.209 .056
Mxi-1 C 0.193/0.192 .179
P value in bold indicates significance.
C indicates cytoplasmic; N , nuclear.
*Student’s t test for paired samples computed for 95% confidence interval.
Figure 2. TrxR1 immunostaining in (A) AS-BP, (B) AS-CaP, and (C) CR-CaP tissue specimens.
Table 2. Comparison of TrxR1 Expression in AS-BP, AS-CaP, and CR-CaP in Prostate TMA.
Epithelia Stroma P
AS-BP 2.88 ± 0.50 1.69 ± 0.48 >.05
AS-CaP 2.59 ± 0.62 1.35 ± 0.49 >.05
CR-CaP 3.47 ± 1.07 2.18 ± 1.13 <.01
Student’s t test computed at 95% confidence interval.
156 TrxR1 Expression and Prostate Cancer Singh et al. Translational Oncology Vol. 1, No. 3, 2008
which catalyzes the nicotinamide adenine dinucleotide phosphate–
dependent reduction of active disulfide sites of Trx to a di-thiol. Hu-
mans have three isoforms of TrxRs, namely TrxR1, TrxR2, and
TrxR3. Although Trx is predominantly cytosolic, it quickly translo-
cates into the nucleus in response to NF-κB activation by UVB irra-
diation or tumor necrosis factor α treatment [20]. In this study,
TrxR1 expression was predominantly nuclear in CWR22 tumors
50 days after castration. The reasons for nuclear expression of TrxR1
in CWR22 tumors require further study.
Thioredoxin increases the DNA-binding activity of number of
transcription factors, including AP-1, AP-2, nuclear receptors, in-
cluding glucocorticoid and estrogen receptors [21]. A variety of po-
tent TrxR inhibitors has been shown to alter the cancer-related
properties of tumors and malignant cells. For example, 1,2-[bis (2-
benzysoselenazolone-3(2H )-ketone)]ethane, reversed the phenotype
of five human leukemia cell lines [22]. Yoo et al. [23] used TrxR1
knockdown in a mouse cancer cell line driven by the oncogene k-
ras to demonstrate the need for TrxR1 expression for cancer growth.
Reduction of TrxR activity in human hepatocellular carcinoma cells
by transfection of TrxR antisense RNA inhibited cell growth [24].
Thioredoxin expression was also found to be associated with lymph
node status and prognosis in early operable non–small cell lung
cancer [25]. Baker et al. [26] found Trx-binding protein, a possible
tumor-suppressor gene, when induced in response to hypoxia in pan-
creatic cancer cells resulted in increased apoptosis and increased sen-
sitivity to platinum anticancer therapy. Increased Trx expression in
human colorectal cancer was found to be associated with decreased
patient survival [27]. Thioredoxin reductase 1 has therefore been im-
plicated as a potential target for cancer therapy [28].
Among nine proteins differentially expressed in androgen-stimulated
versus castration-recurrent CWR tumors, only TrxR1 was differentially
expressed in proliferation versus nonproliferating cells at the onset of
recurrent growth 50 days after castration. Rigorous testing was made
possible by the development of a dual immunostaining method and
quantitative image analysis. The CWR22 model was used to associate
TrxR1 with the earliest possible onset of castration-recurrent growth.
Increase in TrxR1 expression in human CR-CaP specimens is consis-
tent with increased TrxR1 and BrdU expression in the CWR22model.
Thioredoxin reductase 1 should be targeted to delay or prevent CaP
recurrence after castration.
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